Gen-Probe Announces Webcast of First Quarter 2005 Earnings Conference

    Business Editors

    SAN DIEGO--(BUSINESS WIRE)--April 7, 2005--Gen-Probe Incorporated (NASDAQ:GPRO) announced today that it will release its first quarter 2005 financial results on Wednesday, May 4, 2005 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call at 4:30 p.m. ET hosted by Henry L. Nordhoff, chairman, president and CEO, and Herm Rosenman, vice president, finance and CFO.
    The conference call will be webcast live and may be accessed on the investor relations section of the Company's web site at www.gen-probe.com. Following the conference call, an archived version of the webcast will be available on the same web site for at least 90 days. A replay also will be available for approximately 24 hours after the call ends. To access the replay, please call 800-337-5619 (U.S.) or 402-220-9652 (international).

    About Gen-Probe

    Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used to diagnose human diseases and screen donated human blood. Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. The Company also developed and manufactures the only FDA-approved blood screening assay for the simultaneous detection of HIV-1 and HCV, which is marketed by Chiron Corporation. In addition, Gen-Probe's TIGRIS instrument is the only fully automated, high- throughput NAT system for diagnostics and blood screening. Gen-Probe has more than 20 years of NAT expertise, and its products are used daily in clinical laboratories and blood collection centers worldwide. Gen-Probe is headquartered in San Diego and employs approximately 900 people. For more information, go to www.gen-probe.com.

    Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those relating to the use and effectiveness of our products and our collaborations and other agreements with third parties to develop, manufacture and market our products, are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-K for the year ended December 31, 2004, and all subsequent periodic fillings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

--30--JC/cg*

CONTACT: Gen-Probe Incorporated Paula Izidoro (Investor Relations), 858-410-8904

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MEDICAL EARNINGS CONFERENCE CALLS SOURCE: Gen-Probe Incorporated

Copyright Business Wire 2005